WilmerHale Counsels Exonics Therapeutics in $5M Seed Financing

Download IconDownload Print IconPrint

WilmerHale Counsels Exonics Therapeutics in $5M Seed Financing

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Helping clients launch their businesses and transform their innovative ideas into successful companies.

Exonics Therapeutics, Inc., a newly formed biotechnology company focused on developing gene editing technologies to permanently correct a majority of mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, announced a commitment of $5 million in seed financing from CureDuchenne Ventures. The initial seed funding will allow Exonics to advance the preclinical research of its Scientific Founder and Chief Science Advisor Eric Olson, PhD.

The WilmerHale team representing Exonics Therapeutics was led by Gary Schall.

Read Exonics Therapeutics' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel